Ryan Martins - 89bio Chief Officer
| ETNB Stock | USD 8.98 0.16 1.75% |
Insider
Ryan Martins is Chief Officer of 89bio Inc
| Age | 45 |
| Address | 142 Sansome Street, San Francisco, CA, United States, 94104 |
| Phone | 415 432 9270 |
| Web | https://www.89bio.com |
Ryan Martins Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ryan Martins against 89bio stock is an integral part of due diligence when investing in 89bio. Ryan Martins insider activity provides valuable insight into whether 89bio is net buyers or sellers over its current business cycle. Note, 89bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell 89bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ryan Martins over three months ago Disposition of 2018 shares by Ryan Martins of 89bio at 18.95 subject to Rule 16b-3 |
89bio Management Efficiency
The company has return on total asset (ROA) of (0.4136) % which means that it has lost $0.4136 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7331) %, meaning that it created substantial loss on money invested by shareholders. 89bio's management efficiency ratios could be used to measure how well 89bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.25. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, 89bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Net Tangible Assets are forecasted to decline to about 122 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Dr III | Cue Biopharma | 48 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| , MBA | Molecular Partners AG | 51 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Mark Lappe | Inhibrx | 57 | |
| James JD | Eliem Therapeutics | 58 | |
| Kenneth MD | Cue Biopharma | 64 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| BS CPA | Inhibrx | 42 | |
| Steven Almo | Cue Biopharma | 63 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Quinn Deveraux | Inhibrx | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| JD MSc | Cue Biopharma | 61 | |
Management Performance
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.41 |
89bio Inc Leadership Team
Elected by the shareholders, the 89bio's board of directors comprises two types of representatives: 89bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 89bio. The board's role is to monitor 89bio's management team and ensure that shareholders' interests are well served. 89bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 89bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Harry MD, Chief Officer | ||
| Francis Sarena, Chief Officer | ||
| Rohan Palekar, CEO Director | ||
| Quoc LeNguyen, Chief Quality | ||
| Shiva CPA, Senior Officer | ||
| Shiva Natarajan, Senior Officer | ||
| Amanda Hill, VP Culture | ||
| Melissa Abel, VP Communications | ||
| Ryan Martins, Chief Officer | ||
| Paul Shin, Senior Operations | ||
| Yun Bai, Manufacturing Chemistry | ||
| Annie MBA, VP Communications | ||
| Michael Baldwin, VP Quality | ||
| Amanda Kurihara, Vice Culture |
89bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 89bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 688.5 M | ||||
| Shares Outstanding | 117.58 M | ||||
| Shares Owned By Insiders | 0.58 % | ||||
| Shares Owned By Institutions | 93.66 % | ||||
| Number Of Shares Shorted | 5.52 M | ||||
| Price To Earning | (1.04) X | ||||
| Price To Book | 2.84 X | ||||
| EBITDA | (134.46 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether 89bio Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of 89bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of 89bio Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on 89bio Inc Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 89bio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 89bio. If investors know 89bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 89bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Return On Assets (0.41) | Return On Equity (0.73) |
The market value of 89bio Inc is measured differently than its book value, which is the value of 89bio that is recorded on the company's balance sheet. Investors also form their own opinion of 89bio's value that differs from its market value or its book value, called intrinsic value, which is 89bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 89bio's market value can be influenced by many factors that don't directly affect 89bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 89bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if 89bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 89bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.